In a randomized, controlled trial involving adults from Papua New Guinea with Wuchereria bancrofti microfilaremia, the three-drug regimen of ivermectin + diethylcarbamazine + albendazole induced clearance of microfilariae from the blood for 3 years in almost all participants who received the treatment and was superior to the two-drug regimen of diethylcarbamazine + albendazole administered once and noninferior to the two-drug regimen administered once a year for 3 years. These findings are published in the New England Journal of Medicine, Nov. 8, 2018.